SCHEMBL3588871

SCHEMBL3588871

COc1cccc2c1S(=O)(=O)NNC2C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.40
USP2 O75604 1/20 0.40
KMT2A Q03164 1/20 0.40
KDM4E B2RXH2 3/20 0.38
GAA P10253 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
HTR2C P28335 4/20 0.36
HTR1A P08908 2/20 0.36
HTR1D P28221 2/20 0.36
HTR7 P34969 2/20 0.36
HTR5A P47898 2/20 0.36
ALDH1A1 P00352 4/20 0.36
MAPT P10636 3/20 0.34
HPGD P15428 2/20 0.34
HTT P42858 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3589386 0.83 KDM4E (0.41) KMT2AKDM4ECYP2C19ALDH1A1MAPT
SCHEMBL3595544 0.82 KDM4E (0.32) KDM4EHTR2CALDH1A1MAPTHTT
SCHEMBL3588622 0.69 ALDH1A1 (0.38) MEN1USP2KMT2AKDM4ECA1
SCHEMBL2790941 0.66 HTR2C (0.39) MEN1USP2KMT2AKDM4EGAA
SCHEMBL18726136 0.62 KMT2A (0.46) MEN1USP2KMT2AKDM4ECYP3A4
SCHEMBL24029272 0.60 HSD11B1 (0.46) MEN1USP2KMT2ACYP2D6HTR2C
SCHEMBL16470960 0.59 MEN1 (0.39) MEN1USP2KMT2AKDM4EGAA
SCHEMBL32667542 0.59 CA12 (0.44) KMT2AKDM4ECA1CA2MAPT
SCHEMBL30878610 0.58 HSD11B1 (0.54) MEN1KMT2ACYP2D6HTR1AHTR5A
SCHEMBL9828466 0.58 HTR2C (0.46) MEN1USP2KMT2ACYP2D6HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190778-A1 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENTARSASAG (HU) 2010-07-29 US disclosed
EP-2064197-A2 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE Egis Gyogyszergyar Nyilvánosan Múködó Részvénytársaság (HU) 2009-06-03 EP disclosed
WO-2008020256-A2 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE EGIS GYÓGYSZERGYÁR_Nyilvánosan Müködö Részvénytársaság (HU) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190778-A1 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE TDO2, DHODH, DHPS MEN1 863/4885USP2 2798/4885KMT2A 2258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.